Side by side

1. 1.The GHRH fragment binds pituitary GHRH receptors, priming growth-hormone release.
2. 2.Ipamorelin acts on the ghrelin receptor, GHS-R1a, to trigger the release itself.
3. 3.Together they are said to produce a larger pulse than either alone — shown in growth-hormone testing, but never linked to a proven body-composition or recovery outcome.
4. 4.Both are short-acting, so a dose produces a brief pulse rather than sustained elevation.
5. 5.IGF-1 rises secondarily with repeated use.

• Growth-hormone secretion and pulsatility research
• Body-composition and recovery claims, without trials
• Sleep and 'anti-ageing' claims, anecdote only
• Diagnostic growth-hormone stimulation testing for the GHRH component

• A measurable growth-hormone pulse after dosing
• Modest IGF-1 increase with repeated use
• Reported improved sleep and recovery from user accounts
• Fluid retention and joint stiffness, as with the growth-hormone class

• Headache, flushing and dizziness
• Water retention and joint aches
• Tingling or numbness in the hands
• Increased appetite
• Unknown long-term effects of chronic IGF-1 elevation

Research context only — no approved protocol exists. Community schedules use roughly 200 micrograms of each peptide once or twice daily, cycling 8–12 weeks on with 2–4 weeks off; 12 syringe units from a 3 ml reconstitution is a common vendor figure. None of this has been evaluated in a trial, and units depend on the exact concentrations in the vial.

Research context only